These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16048955)

  • 1. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.
    Laffly E; Danjou L; Condemine F; Vidal D; Drouet E; Lefranc MP; Bottex C; Thullier P
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3414-20. PubMed ID: 16048955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive vaccination with a human monoclonal antibody: generation of antibodies and studies for efficacy in Bacillus anthracis infections.
    vor dem Esche U; Huber M; Zgaga-Griesz A; Grunow R; Beyer W; Hahn U; Bessler WG
    Immunobiology; 2011 Jul; 216(7):847-53. PubMed ID: 21397977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.
    Pelat T; Hust M; Laffly E; Condemine F; Bottex C; Vidal D; Lefranc MP; Dübel S; Thullier P
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2758-64. PubMed ID: 17517846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library.
    Chassagne S; Laffly E; Drouet E; Hérodin F; Lefranc MP; Thullier P
    Mol Immunol; 2004 Jul; 41(5):539-46. PubMed ID: 15183932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
    Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
    Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis.
    Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R
    Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
    Yan M; Roehrl MH; Basar E; Wang JY
    Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and evaluation of human-murine chimeric antibody against protective antigen of Bacillus anthracis.
    Hao L; Zheng F; Xiong S; Hu D; Lv H; Tang Q; Yang J; Feng Z; Wang C; Zhu J
    Int J Mol Sci; 2014 Oct; 15(10):18496-507. PubMed ID: 25318053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
    Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R
    Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax.
    Tang Q; Xiong S; Liang X; Kuai X; Wang Y; Wang C; Feng Z; Zhu J
    BMC Infect Dis; 2018 Dec; 18(1):640. PubMed ID: 30526504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops.
    Laffly E; Pelat T; Cédrone F; Blésa S; Bedouelle H; Thullier P
    J Mol Biol; 2008 May; 378(5):1094-103. PubMed ID: 18423488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies.
    Brossier F; Lévy M; Landier A; Lafaye P; Mock M
    Infect Immun; 2004 Nov; 72(11):6313-7. PubMed ID: 15501759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.
    Chen Z; Moayeri M; Crown D; Emerson S; Gorshkova I; Schuck P; Leppla SH; Purcell RH
    Infect Immun; 2009 Sep; 77(9):3902-8. PubMed ID: 19528217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.
    Kelly-Cirino CD; Mantis NJ
    Infect Immun; 2009 Nov; 77(11):4859-67. PubMed ID: 19703971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.
    Maynard JA; Maassen CB; Leppla SH; Brasky K; Patterson JL; Iverson BL; Georgiou G
    Nat Biotechnol; 2002 Jun; 20(6):597-601. PubMed ID: 12042864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paratope diversity in the human antibody response to Bacillus anthracis protective antigen.
    Zhou J; Ullal A; Liberato J; Sun J; Keitel W; Reason DC
    Mol Immunol; 2008 Jan; 45(2):338-47. PubMed ID: 17707509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
    Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
    Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.
    Moayeri M; Leysath CE; Tremblay JM; Vrentas C; Crown D; Leppla SH; Shoemaker CB
    J Biol Chem; 2015 Mar; 290(10):6584-95. PubMed ID: 25564615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen.
    Steiniger SC; Altobell LJ; Zhou B; Janda KD
    Mol Immunol; 2007 Apr; 44(10):2749-55. PubMed ID: 17210180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro.
    Ding G; Chen X; Zhu J; Duesbery NS; Cheng X; Cao B
    Clin Dev Immunol; 2013; 2013():475809. PubMed ID: 23861692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.